SANGAMO THERAPEUTICS, INC (SGMO): Nasdaq/NYSE listing notice — Sangamo receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

SANGAMO THERAPEUTICS, INC

On April 30, 2025, Nasdaq notified Sangamo that its stock closed below $1.00 for 30 consecutive business days.
Company has until October 27, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant, may qualify for a second 180-day period if other listing standards are met.
Failure to cure could result in delisting from the Nasdaq Capital Market.
Sangamo will monitor bid price and evaluate options including a reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 30, 2025, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance wi

View on SEC.gov

Browse all listing & compliance notices →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-25-022664

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.